Hansa Biopharma AB - Company Profile
Powered by
All the data and insights you need on Hansa Biopharma AB in one report.
- Save hours of research time and resources with
our up-to-date Hansa Biopharma AB Strategy Report
- Understand Hansa Biopharma AB position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Hansa Biopharma AB (Hansa Biopharma) focuses on the development of novel immunomodulatory enzymes for the treatment of rare and acute medical conditions characterized by pathogenic antibodies. Focus on innovation, partnerships and agreements and HBP-Assay method are its strengths, while operating loss carry forward could be an area for concern. The company could benefit from Orphan Drug designation for IdeS, strategic agreement and changing demographics. Nevertheless, its performance can be affected by uncertain R&D outcomes, government regulations and competitive environment.
Strengths
Weaknesses
Opportunities
Threats
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer